Based on the amyloid hypothesis, Aβ is considered one of the leading potential causes of AD, so inhibition of BACE1 to reduce the production of Aβ is considered to be an effective strategy for AD treatment (Yan & Vassar, 2014). Here, BACE1 is linked to Alzheimer disease.